Lenalidomide Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, which changes the complex’s substrate preference. This leads to the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, reducing tumor‑cell proliferation, enhancing immune‑mediated killing, and inhibiting new blood‑vessel formation.

The specific dose of Lenalidomide Zentiva is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s written instructions and local regulatory guidelines.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception. The safety of lenalidomide during breastfeeding has not been established, and nursing is generally not recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and may provide benefits in patients who have relapsed after other therapies. Choice of therapy depends on disease characteristics, prior treatment exposure, and patient tolerance.

Lenalidomide Zentiva tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually as a whole tablet with water. It is typically prescribed on a cyclical schedule (e.g., daily for a set number of days followed by a rest period), but the exact regimen is defined by the treating physician based on the individual treatment plan.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe skin reactions like Stevens‑Johnson syndrome, and the potential development of secondary primary malignancies. Patients should be monitored closely for signs of these events and report any unusual symptoms promptly.

Lenalidomide is contraindicated in pregnant women and should not be used by individuals who cannot comply with effective contraception. Patients with uncontrolled infections, severe renal impairment without dose adjustment, or known hypersensitivity to lenalidomide or its excipients should avoid the drug.